Evidence map›Paper›PMID 28718728›Full record

Trial reportLeukemia & lymphoma2018

A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.

Nicholas J Short, Hagop Kantarjian, Farhad Ravandi, Xuelin Huang, Lianchun Xiao, Guillermo Garcia-Manero, William Plunkett, Varsha Gandhi, Koji Sasaki, Naveen Pemmaraju and 12 more

Open access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase IIComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Therapeutic Advances in Immunotherapies for Hematological Malignancies.International journal of molecular sciences · 2022
    Review
  8. Review
  9. Review
  10. Targeting CXCR4 in AML and ALL.Frontiers in oncology · 2020
    Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Nicholas J Shorta Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Hagop Kantarjiana Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Farhad Ravandia Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Xuelin Huangb Department of Biostatistics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Lianchun Xiaob Department of Biostatistics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Guillermo Garcia-Maneroa Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
William Plunkettc Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Varsha Gandhic Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Koji Sasakid Division of Cancer Medicine , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Naveen Pemmarajua Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Naval G Davera Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Gautam Borthakura Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.ORCID 0000-0001-7679-6453
Nitin Jaina Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Marina Konoplevaa Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Zeev Estrova Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Tapan M Kadiaa Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
William G Wierdaa Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Courtney D DiNardoa Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Mark Brandta Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Susan M O'Brienc Department of Experimental Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Jorge E Cortesa Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Elias Jabboura Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

The purine nucleoside analogues clofarabine and fludarabine are active in acute myeloid leukemia (AML). We conducted a phase I/II randomized study of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) for relapsed or refractory AML. Clofarabine 15 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBone MarrowClofarabineCytarabineDrug Resistance, NeoplasmHumansIdarubicinLeukemia, Myeloid, AcuteMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalRemission InductionSurvival RateTreatment OutcomeClofarabineCytarabinefludarabineIdarubicinVidarabineAcute myeloid leukemiaclofarabinefludarabinepurine nucleoside analoguesrefractoryrelapsed

Identifiers

PMID28718728
PMCPMC5773400
OpenAlexW2738123701

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.